Skip to content

HCSC

Does HCSC cover Wegovy?

Yes. HCSC covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult weight management

All of:

  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
  • Patient is an adult (18 years of age or over)
  • Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
  • Patient is currently on and will continue weight management regimen in combination with the requested agent
  • Patient will NOT use requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • ONE of the Wegovy continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained ≥ 5% weight loss from baseline

Plus any one of:

  • Pretreatment BMI ≥ 30 kg/m2
  • Pretreatment BMI ≥ 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
  • Pretreatment BMI ≥ 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric weight management (12-17 years)

All of:

  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
  • Patient is pediatric (12 to 17 years of age)
  • Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
  • Patient is currently on and will continue weight management regimen in combination with the requested agent
  • Patient will NOT use requested agent in combination with another weight loss agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • ONE of the Wegovy continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained ≥ 5% BMI reduction from baseline (pediatric)

Plus any one of:

  • Pretreatment BMI ≥ 95th percentile for age and sex
  • Pretreatment BMI ≥ 30 kg/m2
  • Pretreatment BMI ≥ 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Another FDA labeled indication (weight management pathway override)

All of:

  • Patient has another FDA labeled indication for the requested agent and route of administration
  • Patient will NOT use requested agent in combination with another weight loss agent
  • Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications
  • Patient is currently on and will continue weight management regimen

Documentation to bring

  • Baseline BMI documentation
  • Documentation of at least 6 months of inadequate response to low-calorie diet, increased physical activity, and behavioral modifications (for initial approval)
  • Documentation that patient is currently on weight management regimen (diet, physical activity, behavioral modifications)
  • For Asian descent patients: documentation of ethnicity supporting lower BMI threshold
  • For patients with comorbidities qualifying at BMI ≥ 27: documentation of qualifying comorbidity
  • For pediatric patients: documentation of BMI percentile for age and sex
  • Confirmation that patient will not combine with another weight loss agent or GLP-1 RA
  • For continuation: documentation of weight loss ≥ 5% from baseline (adults) or BMI reduction ≥ 5% from baseline (pediatric), OR documentation of being within 52 weeks of therapy on maximum-tolerated dose

Quantity limits

  • 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML — 8 pens per 180-day supply (84-day)
  • 1.7 MG/0.75ML, 2.4 MG/0.75ML — 4 pens per 28-day supply
  • 7.2 MG/0.75ML — 4 pens per 28-day supply
  • 1.5 MG tablet, 4 MG tablet, 9 MG tablet — 60 tablets per 180-day supply (84-day)
  • 25 MG tablet — 30 tablets per 30-day supply

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At least 5% reduction in BMI.
  • Renewal: For renewal (weight management): patient must have received less than 52 weeks of therapy on the maximum-tolerated dose OR achieved and maintained ≥ 5% weight loss from baseline (adults) OR ≥ 5% BMI reduction from baseline (pediatric). Pediatric patients must also maintain BMI ≥ 85th percentile at renewal. Initial BMI thresholds and 6-month lifestyle program pre-therapy requirement are not re-verified at renewal. Wegovy-specific: patient currently on and must continue low-calorie diet, increased physical activity, and behavioral modifications; must not combine with another weight loss agent or another GLP-1 RA.

Not covered when

  • Combination use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Combination use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Exceptions

  • BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
  • Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals supporting proposed use as generally safe and effective.

Policy note: Approval duration for BCBS IL HIM/FI/ASO Cost (BBF) and BCBSMT FI & HIM is 12 months. For all other plans: initial approval is 12 months; renewal is 12 months. Wegovy 0.5mg and 1mg injections may be approved for maintenance therapy at quantity limit if patient cannot use an FDA labeled maintenance strength and has had clinical benefit. Wegovy 4mg and 9mg tablets similarly may be approved for maintenance if patient cannot use an FDA labeled maintenance strength. Quantity limit exception also available if patient has had clinical benefit on lower strength from baseline.

Policy effective May 18, 2026 · verified June 2, 2026 · source: Hcsc Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CVD and obesity/overweight

All of:

  • Requested use is to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
  • Requested agent is Wegovy
  • Patient has a pretreatment BMI ≥ 27 kg/m2
  • Patient will use optimized pharmacotherapy for established cardiovascular disease in combination with Wegovy
  • Patient does NOT have any FDA labeled contraindications

Plus any one of:

  • History of myocardial infarction
  • History of stroke
  • Peripheral artery disease as defined by intermittent claudication with ankle-brachial index < 0.85 at rest, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of established cardiovascular disease (CAD, ACS, history of MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid or arterial stenosis, PAD including aortic aneurysm, all of atherosclerotic origin)
  • Documentation of qualifying CV event: MI, stroke, or PAD (with ABI < 0.85, revascularization, or amputation due to atherosclerotic disease)
  • Baseline BMI documentation (≥ 27 kg/m2)
  • Documentation of current or planned optimized pharmacotherapy for established cardiovascular disease

Quantity limits

  • 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML — 8 pens per 180-day supply (84-day)
  • 1.7 MG/0.75ML, 2.4 MG/0.75ML — 4 pens per 28-day supply
  • 7.2 MG/0.75ML — 4 pens per 28-day supply
  • 1.5 MG tablet, 4 MG tablet, 9 MG tablet — 60 tablets per 180-day supply (84-day)
  • 25 MG tablet — 30 tablets per 30-day supply

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At renewal, patient must have had clinical benefit with Wegovy AND will continue optimized pharmacotherapy for established cardiovascular disease. Initial qualifying CV event documentation and BMI threshold are not explicitly re-verified at renewal.

Not covered when

  • Any FDA labeled contraindications to the requested agent

Exceptions

  • BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
  • Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.

Policy note: Established CVD is defined broadly as: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin. The PAD qualifying criterion specifically requires: intermittent claudication with ABI < 0.85 at rest, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease. GDMT specified as 'optimized pharmacotherapy for established cardiovascular disease' without naming specific drug classes.

Policy effective May 18, 2026 · verified June 2, 2026 · source: Hcsc Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with moderate to advanced fibrosis (F2-F3)

All of:

  • Diagnosis of noncirrhotic MASH (formerly NASH) with moderate to advanced liver fibrosis consistent with stages F2 to F3 (medical records required)
  • Stage F2 or F3 fibrosis confirmed by one of: liver biopsy, VCTE, ELF score, or MRE (prior to therapy)
  • Requested agent is Wegovy injection
  • Patient is an adult (18 years of age or over)
  • Patient is being monitored and/or treated for any comorbid conditions (e.g., CVD, diabetes, dyslipidemia, hypertension)
  • Patient does NOT have decompensated cirrhosis
  • Patient does NOT have moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Patient does NOT have any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist) OR has consulted with such a specialist

Plus any one of:

  • If patient's sex is female: alcohol consumption < 20 grams/day
  • If patient's sex is male: alcohol consumption < 30 grams/day

Documentation to bring

  • Medical records confirming diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • Fibrosis staging confirmation via one of: liver biopsy report, VCTE result, ELF score result, or MRE result (prior to therapy initiation)
  • Documentation of alcohol consumption (< 20g/day for females, < 30g/day for males)
  • Documentation of monitoring and/or treatment of comorbid conditions (CVD, diabetes, dyslipidemia, hypertension)
  • Documentation confirming absence of: decompensated cirrhosis, Child-Pugh Class B or C hepatic impairment, other liver disease (Wilson's disease, HCC, hepatitis)
  • Confirmation that prescriber is a specialist (hepatologist, gastroenterologist) or has consulted with one

Quantity limits

  • 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML — 8 pens per 180-day supply (84-day)
  • 1.7 MG/0.75ML, 2.4 MG/0.75ML — 4 pens per 28-day supply
  • 7.2 MG/0.75ML — 4 pens per 28-day supply

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At renewal, patient must have had clinical benefit with Wegovy. Alcohol consumption limits (<20g/day female, <30g/day male) re-verified. Hepatic exclusions (decompensated cirrhosis, Child-Pugh B/C, other liver disease) re-verified. Specialist requirement re-verified. Stage F2/F3 fibrosis confirmation via biopsy/imaging is NOT re-required at renewal.

Not covered when

  • Decompensated cirrhosis
  • Moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Cirrhotic MASH (noncirrhotic required)
  • Any FDA labeled contraindications to the requested agent

Exceptions

  • BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
  • Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.

Policy note: Applicable only to Wegovy injection formulation (not Wegovy tablets). Fibrosis must be confirmed prior to therapy initiation. No explicit lookback period stated for biopsy or imaging. Alcohol limits: <20g/day female, <30g/day male (note: one standard drink ~14g). Document notes one standard drink = 12oz regular beer, 5oz wine, or 1.5oz distilled spirits.

Policy effective May 18, 2026 · verified June 2, 2026 · source: Hcsc Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does HCSC cover Wegovy?
Yes. HCSC covers Wegovy for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with HCSC?
Weight Loss — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Liver Disease (MASH) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does HCSC require to renew Wegovy?
Weight Loss — Applies to Employer plans. At least 5% reduction in BMI. For renewal (weight management): patient must have received less than 52 weeks of therapy on the maximum-tolerated dose OR achieved and maintained ≥ 5% weight loss from baseline (adults) OR ≥ 5% BMI reduction from baseline (pediatric). Pediatric patients must also maintain BMI ≥ 85th percentile at renewal. Initial BMI thresholds and 6-month lifestyle program pre-therapy requirement are not re-verified at renewal. Wegovy-specific: patient currently on and must continue low-calorie diet, increased physical activity, and behavioral modifications; must not combine with another weight loss agent or another GLP-1 RA. Heart Disease Risk Reduction — Applies to Employer plans. At renewal, patient must have had clinical benefit with Wegovy AND will continue optimized pharmacotherapy for established cardiovascular disease. Initial qualifying CV event documentation and BMI threshold are not explicitly re-verified at renewal. Liver Disease (MASH) — Applies to Employer plans. At renewal, patient must have had clinical benefit with Wegovy. Alcohol consumption limits (<20g/day female, <30g/day male) re-verified. Hepatic exclusions (decompensated cirrhosis, Child-Pugh B/C, other liver disease) re-verified. Specialist requirement re-verified. Stage F2/F3 fibrosis confirmation via biopsy/imaging is NOT re-required at renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under HCSC: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Illinois Medicaid, Molina Healthcare, Oklahoma Medicaid, Elevance Health, Highmark, Premera, Regence, Wellmark

All insurance plans · All medications

Summary of HCSC's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.